Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

YM-90709

YM-90709 is a novel, selective inhibitor of interleukin-5 (IL-5).
Catalog #: B1074

In stock

SKU-Size Size Price Qty
B1074-10 10 mg
$145.00
B1074-50 50 mg
$495.00
More Sizes Get Quote

Product Details

Alternate Name 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-b]quinoxaline
Appearance Yellow solid
CAS # 163769-88-8
Molecular Formula C₂₂H₂₁N₃O₂
Molecular Weight 359.43
Purity ≥98% by HPLC
Solubility DMSO (>15 mg/ml)
SMILES CC1(CC2=CC(=C(C=C2C3=CC4=NC5=CC=CC=C5N=C4N31)OC)OC)C
InChi InChI=1S/C22H21N3O2/c1-22(2)12-13-9-19(26-3)20(27-4)10-14(13)18-11-17-21(25(18)22)24-16-8-6-5-7-15(16)23-17/h5-11H,12H2,1-4H3
InChi Key HIXSPVQXXDULHS-UHFFFAOYSA-N
PubChem CID 1103147
Handling Protect from air and light
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

YM-90709 is a selective inhibitor of interleukin-5 (IL-5). YM-90709 inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells, with IC₅₀ values of 1.0 and 0.57 µM, respectively. In functional assays, YM-90709 inhibits IL-5-prolonged eosinophil survival with an IC₅₀ value of 0.45 µM and does not affect the GM-CSF-prolonged eosinophil survival.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.